Abstract

Background: Glioblastoma (GBM) is the frequently occurring and most aggressive form of brain tumors. In the study, we constructed an immune-related gene pairs (IRGPs) signature to predict overall survival (OS) in patients with GBM.Methods: We established IRGPs with immune-related gene (IRG) matrix from The Cancer Genome Atlas (TCGA) database (Training cohort). After screened by the univariate regression analysis and least absolute shrinkage and selection operator (LASSO) regression analysis, IRGPs were subjected to the multivariable Cox regression to develop an IRGP signature. Then, the predicting accuracy of the signature was assessed with the area under the receiver operating characteristic curve (AUC) and validated the result using the Chinese Glioma Genome Atlas (CGGA) database (Validation cohorts 1 and 2).Results: A 10-IRGP signature was established for predicting the OS of patients with GBM. The AUC for predicting 1-, 3-, and 5-year OS in Training cohort was 0.801, 0.901, and 0.964, respectively, in line with the AUC of Validation cohorts 1 and 2 [Validation cohort 1 (1 year: 0.763; 3 years: 0.786; and 5 years: 0.884); Validation cohort 2 (1 year: 0.745; 3 years: 0.989; and 5 years: 0.987)]. Moreover, survival analysis in three cohorts suggested that patients with low-risk GBM had better clinical outcomes than patients with high-risk GBM. The univariate and multivariable Cox regression demonstrated that the IRGPs signature was an independent prognostic factor.Conclusions: We developed a novel IRGPs signature for predicting OS in patients with GBM.

Highlights

  • Glioma is the most common and the most aggressive cancer of the central nervous system [1]

  • With the univariate regression analysis, 48 immune-related gene pairs (IRGPs) were filtered in the Training cohort

  • The least absolute shrinkage and selection operator (LASSO) regression analysis screened out 24 IRGPs for further analysis (Figure 1A)

Read more

Summary

Introduction

Glioma is the most common and the most aggressive cancer of the central nervous system [1]. Like surgery, chemotherapy, targeted therapy, and so on, had been applied for GBM, the 5-year relative survival probability of GBM is only limited to 6.8% [3], and the median lifespan is only 19.2 months [4]. Due to these discouraging survival data, the development of more accurate tumor-specific biomarkers of GBM for further constructing novel diagnostic signature and guiding clinical treatment is still a priority in GBM management. We constructed an immune-related gene pairs (IRGPs) signature to predict overall survival (OS) in patients with GBM

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call